South Korea’s Samsung Biologics has completed its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first U.S. manufacturing presence. The deal was first announced in late 2025.

The Rockville site includes two cGMP manufacturing plants with a combined 60,000 liters of drug substance capacity supporting both clinical and commercial biologics production across multiple scales. With the acquisition, Samsung Biologics said its total global manufacturing capacity increases to 845,000 liters.

Samsung Biologics said it will continue supplying products previously manufactured at the site to GSK under the terms of the agreement, while transitioning the facility to support additional contract manufacturing needs. The company also plans further investments to expand capacity and upgrade technologies at the site.

More than 500 employees at the Rockville facility will join Samsung Biologics as part of the acquisition, according to the announcement.

The acquisition adds to recent expansion efforts by Samsung Biologics. Earlier last month, the company and Eli Lilly announced plans to establish a Lilly Gateway Labs site at Samsung Biologics’ Bio Campus II in Incheon, South Korea. According to the companies, the 125,000-square-foot facility is expected to open in 2027 and will support up to 30 early-stage biotech firms focused on drug development and manufacturing collaboration.